Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

Abstract

The high cost of direct-acting antiviral-based regimens raises concerns about the outcome of treatment in uninsured patients with chronic hepatitis C virus (HCV) infection. This study assessed the relationship between health insurance status and sustained virologic response (SVR) rates in a community hospital in South Florida. Sofosbuvir-based therapy was initiated in 82 patients, of which 73% were uninsured and 28 (34%) were HIV coinfection. The overall SVR rate for those tested was 98%. The SVR rates were similar between HCV mono- and HCV/HIV coinfected patients (96% versus 100%, P = .204). Uninsured patients, with access to patient assistance programs, had comparable SVR rates to insured patients (100% versus 95%, P = .131). However, there was a trend toward a higher rate of loss to follow-up in uninsured compared to insured patients (25% versus 9%, P = .116). Strategies specific to adherence to treatment for uninsured patients are needed to reduce rates of loss to follow-up.

Authors

Eckardt P1, Niu J2, Savage A1, Griffin T1, Sherman E1,3.

 

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219835590. doi: 10.1177/2325958219835590.

Author Information

  1. Division of Infectious Diseases, Memorial Physician Group, Hollywood, FL, USA.

  2. Office of Human Research, Memorial Healthcare System, Hollywood, FL, USA.

  3. Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA.

  • RhAPP Facebook
  • RhAPP Twitter
  • RhAPP Instagram
RhAPP Logo_WHT.png

© Rheumatology Advanced Practice Providers